Fresenius Medical Care AG & Co. KGaA is a German healthcare company that provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients....
Fresenius Medical Care AG & Co. KGaA is a German healthcare company that provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. Fresenius also develops and manufactures various dialysis healthcare products and non-dialysis products. North America is Fresenius Medical Care's largest market by far. Founded in 1996, the company operates more than 2,500 of its dialysis clinics there and treats more than 211,000 patients. Fresenius is traded as NYSE: FMS, with an investment grade credit rating of S&P/ Moody's BBB-/Baa3 respectively. 2023 the company’s market cap was $13.36B, and its revenue was $21.10B. The company is 32% owned by Fresenius SE & Co. KGaA and is headquartered in Bad Homburg vor der Hohe, Germany.
Fresenius SE & Co. KGaA is a European multinational healthcare company that provides products and services for dialysis, in hospitals and inpatient and outpatient medical care. It is involved in hospital management, engineering, and services for medical centers and other healthcare facilities. Fresenius operates in four divisions: Fresenius Medical Care, Fresenius Helios, Fresenius Kabi, and Fresenius Vamed. The company is headquartered in Bad Homburg, Germany, and its North American headquarters is in Waltham, MA.